SGLT2 inhibitors (SGLT2i) are used worldwide because of their multiple benefits for patients with type 2 diabetes. The purpose of this study was to determine the efficacy and safety of SGLT2i in patients with type 1 diabetes (T1DM).
Patients with T1DM who had been treated with SGLT2i for >12 weeks were included in this retrospective observation study. We recorded the changes in body mass, insulin dose, blood and urine test data, and adverse events. The changes in day-to-day glucose variability, as the primary endpoint, was evaluated using the interquartile range (P25/P75) of the ambulatory glucose data obtained using continuous glucose monitoring (CGM).
Fifty-one patients (37 women; mean age 52.7 years) were included. HbA1c and body mass significantly decreased by 0.4% and 1.6 kg, respectively. The total required insulin dose decreased by 9.4% (42.7 ± 26.6 to 38.7 ± 24.3 units/day). CGM data were obtained from 30 patients. P25/P75 decreased by 17.6 ± 20.7% during SGLT2i treatment (P<0.001). The percentage of time per day within the target glucose range of 70-180 mg/dL significantly increased (from 42.2% to 55.5%, P<0.001), without an increase in the percentage of time spent in the hypoglycemic range (<70 mg/dL). Urinary ketone bodies were detected in four patients (7.8%), but none developed ketoacidosis.
SGLT2i improved day-to-day glucose variability and time in the target glucose range, without increasing frequency of hypoglycemia, in patients with T1DM, and reduced HbA1c, body mass, and the required insulin dose.

This article is protected by copyright. All rights reserved.

References

PubMed